A49T, V89L and TA repeat polymorphisms of steroid 5α-reductase type II and breast cancer risk in Japanese women
作者： Chunxia Yang , Nobuyuki Hamajima , Hiroji Iwata , Toshiko Saito , Keitaro Matsuo
DOI: 10.1186/BCR445
关键词: Prostate 、 Cancer 、 Biology 、 Testosterone 、 Breast cancer 、 Genotype 、 Endocrinology 、 Dihydrotestosterone 、 Internal medicine 、 Haplotype 、 SRD5A2
摘要: Background Breast cancer is hormone related, as are cancers of the endometrium, ovary, and prostate. Several studies have suggested that higher extracellular levels androgens associated with breast risk, while biological evidence indicates protective. The codon 49 alanine to threonine substitution (A49T), 89 valine leucine (V89L) TA repeat polymorphisms steroid 5α-reductase type II (SRD5A2) gene considered functional respect enzyme activity converting testosterone into dihydrotestosterone. To test hypothesis these three risk cancer, a case–control study was conducted patients Aichi Cancer Center Hospital.
springer.com
biomedcentral.com
core.ac.uk
paperity.org参考文章(30)
B. Budai, M. J. Reed, A. Purohit, J. Kralovánszky, M. Bak, Sz Ottó, Z. Sulyok, M. Német, D. C. Parish, I. Számel, Characteristics of cystic breast disease with special regard to breast cancer development. Anticancer Research. ,vol. 21, pp. 749- 752 ,(2001)
Laurence N. Kolonel, Frank Z. Stanczyk, Nick Makridakis, Malcolm C. Pike, Juergen K. V. Reichardt, Mimi C. Yu, Lilly Chang, Brian E. Henderson, Chen-Yang Shi, Ronald K. Ross, A Prevalent Missense Substitution That Modulates Activity of Prostatic Steroid 5α-Reductase Cancer Research. ,vol. 57, pp. 1020- 1022 ,(1997)
Yves Mérand, Sophie Dauvois, Charles Lévesque, Chang-Shan Geng, Fernand Labrie, Additive inhibitory effects of an androgen and the antiestrogen EM-170 on estradiol-stimulated growth of human ZR-75-1 breast tumors in athymic mice Cancer Research. ,vol. 51, pp. 3131- 3135 ,(1991)
J A Tangrea, R T Falk, H E Stephenson, W S Campbell, L Kahle, R Miller, C Franz, C Longcope, J F Dorgan, A Schatzkin, Relation of prediagnostic serum estrogen and androgen levels to breast cancer risk. Cancer Epidemiology, Biomarkers & Prevention. ,vol. 5, pp. 533- 539 ,(1996)
Nick Makridakis, Malcolm C. Pike, Juergen K. V. Reichardt, Mimi C. Yu, Brian E. Henderson, Ronald K. Ross, Genetic Variability of the Human SRD5A2 Gene: Implications for Prostate Cancer Risk Cancer Research. ,vol. 55, pp. 3973- 3975 ,(1995)
Phillip G Febbo, Philip W Kantoff, Elizabeth A Platz, Daniel Casey, Steve Batter, Edward Giovannucci, Charles H Hennekens, Meir J Stampfer, None, The V89L Polymorphism in the 5α-Reductase Type 2 Gene and Risk of Prostate Cancer Cancer Research. ,vol. 59, pp. 5878- 5881 ,(1999)
Takashi Suzuki, Andrew D. Darnel, Jun-Ichi Akahira, Naohiro Ariga, Sayaka Ogawa, Chika Kaneko, Junji Takeyama, Takuya Moriya, Hironobu Sasano, 5alpha-reductases in human breast carcinoma: possible modulator of in situ androgenic actions. The Journal of Clinical Endocrinology and Metabolism. ,vol. 86, pp. 2250- 2257 ,(2001) , 10.1210/JCEM.86.5.7444
Nobuyuki Hamajima, Toshiko Saito, Keitaro Matsuo, Ken-ichi Kozaki, Takashi Takahashi, Kazuo Tajima, Polymerase chain reaction with confronting two-pair primers for polymorphism genotyping Japanese Journal of Cancer Research. ,vol. 91, pp. 865- 868 ,(2000) , 10.1111/J.1349-7006.2000.TB01026.X
R.K Nam, A Toi, D Vesprini, M Ho, W Chu, S Harvie, J Sweet, J Trachtenberg, M.A.S Jewett, S.A Narod, V89L polymorphism of type-2, 5-alpha reductase enzyme gene predicts prostate cancer presence and progression. Urology. ,vol. 57, pp. 199- 204 ,(2001) , 10.1016/S0090-4295(00)00928-6
Alain G. Latil, Rahm�ne Azzouzi, G�raldine S. Cancel, Emmanuelle C. Guillaume, B�atrix Cochan-Priollet, Philippe L. Berthon, Olivier Cussenot, Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways. Cancer. ,vol. 92, pp. 1130- 1137 ,(2001) , 10.1002/1097-0142(20010901)92:5<1130::AID-CNCR1430>3.0.CO;2-B